131 related articles for article (PubMed ID: 32640926)
1. Effect of the Antiglaucoma Agent JV-GL1 and Related Compounds in the Canine Eye.
Woodward DF; Coleman RA; Woodrooffe AJ; Spada CS; Wang JW
J Ocul Pharmacol Ther; 2020 Oct; 36(8):636-648. PubMed ID: 32640926
[No Abstract] [Full Text] [Related]
2. A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method.
Woodward DF; Wang JW; Coleman RA; Woodrooffe AJ; Clark KL; Stamer WD; Tao G; Fan S; Toris CB
J Ocul Pharmacol Ther; 2019 Jun; 35(5):265-277. PubMed ID: 31025909
[No Abstract] [Full Text] [Related]
3. The role of EP
Bertrand JA; Woodward DF; Sherwood JM; Wang JW; Overby DR
Br J Ophthalmol; 2021 Nov; 105(11):1610-1616. PubMed ID: 33239414
[TBL] [Abstract][Full Text] [Related]
4. In-vivo activity and enzymatic hydrolysis of novel prostaglandin F2 alpha prodrugs in ocular tissues.
Woodward DF; Chan MF; Cheng-Bennett A; Wheeler LA; Chen G; Burke JA; Kharlamb A; Lai RK; Shan T
Exp Eye Res; 1996 Oct; 63(4):411-23. PubMed ID: 8944548
[TBL] [Abstract][Full Text] [Related]
5. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
[TBL] [Abstract][Full Text] [Related]
6. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
[No Abstract] [Full Text] [Related]
7. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
[TBL] [Abstract][Full Text] [Related]
8. Ocular effects of topical 0.03% bimatoprost solution in normotensive feline eyes.
Regnier A; Lemagne C; Ponchet A; Cazalot G; Concordet D; Gelatt KN
Vet Ophthalmol; 2006; 9(1):39-43. PubMed ID: 16409244
[TBL] [Abstract][Full Text] [Related]
9. Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure.
Lee SS; Dibas M; Almazan A; Robinson MR
J Ocul Pharmacol Ther; 2019 Apr; 35(3):138-144. PubMed ID: 30698494
[TBL] [Abstract][Full Text] [Related]
10. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
Sherwood M; Brandt J;
Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
[TBL] [Abstract][Full Text] [Related]
11. Effect of topical prostaglandin PGA2, PGA2 isopropyl ester, and PGF2 alpha isopropyl ester on intraocular pressure in normotensive and glaucomatous canine eyes.
Gum GG; Kingsbury S; Whitley RD; Garcia A; Gelatt KN
J Ocul Pharmacol; 1991; 7(2):107-16. PubMed ID: 1919268
[TBL] [Abstract][Full Text] [Related]
12. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
[TBL] [Abstract][Full Text] [Related]
13. Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting.
Park KH; Simonyi S; Kim CY; Sohn YH; Kook MS
BMC Ophthalmol; 2014 Dec; 14():160. PubMed ID: 25519810
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.
DuBiner H; Cooke D; Dirks M; Stewart WC; VanDenburgh AM; Felix C
Surv Ophthalmol; 2001 May; 45 Suppl 4():S353-60. PubMed ID: 11434938
[TBL] [Abstract][Full Text] [Related]
15. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
16. Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous Beagle.
Gelatt KN; Mackay EO
J Ocul Pharmacol Ther; 2002 Dec; 18(6):525-34. PubMed ID: 12537679
[TBL] [Abstract][Full Text] [Related]
17. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.
Brandt JD; VanDenburgh AM; Chen K; Whitcup SM;
Ophthalmology; 2001 Jun; 108(6):1023-31; discussion 1032. PubMed ID: 11382623
[TBL] [Abstract][Full Text] [Related]
18. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
19. Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.
Seal JR; Robinson MR; Burke J; Bejanian M; Coote M; Attar M
J Ocul Pharmacol Ther; 2019; 35(1):50-57. PubMed ID: 30335560
[TBL] [Abstract][Full Text] [Related]
20. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
